title: Progress in the treatment of diabetes type 1 and 2.
abstract: In the last years an increased incidence of diabetes was observed in the whole world. It was estimated that in the year 2030 there will be around 300 million patients with diabetes. Diabetes, especially not adequately treated, develops serious chronic complications. The main aim of the therapy in diabetes is, as we know, to achieve a stable normoglycemia, normal levels of HbA1c, the prevention or inhibition of the progression of late consequences of diabetes. In the paper the authors discuss new more perfect insulins which enable a better imitation of the physiological rhythm of insulin secretion, the therapy with personal insulin pumps, the more perfect equipment for the appreciation and monitoring of the metabolic control. The authors present also the actual data about the transplantation of the pancreas, the islets and recently the beta cells alone. They enumerate also the inclusion and exclusion criteria for transplantation. The gene therapy is mentioned. The present possibilities of the therapy of type 2 diabetes are presented. It is stressed that in the year 2006 for the first time an expert crew was appointed to elaborate a prevention and therapeutical program for diabetes in Poland. The program was accepted by the Ministry of Health for realisation in the years 2006-2008. The authors conclude that in the recent years an enormous progress in the prevention, diagnostics and therapy in diabetes has been achieved. However, the time which should elapse to the moment when the complete success would be achieved is dependent on the further scientific progress the intensity of investigations in the whole world.
authors.affiliation: Department of Endocrinology and Diabetology for Children and Adolescents, University of Medicine, Wrocław.
authors.forename: Renata B
authors.initials: RB
authors.lastname: Wasikowa
authors.forename: Aleksander
authors.initials: A
authors.lastname: Basiak
mesh_terms: D000818:Animals; D003922:Diabetes Mellitus, Type 1 / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy*; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy*; D018450:Disease Progression; D005260:Female; D015316:Genetic Therapy; D005951:Glucose Tolerance Test; D006442:Glycated Hemoglobin / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D016381:Islets of Langerhans Transplantation; D008297:Male; D008403:Mass Screening; D008687:Metformin / Q000627:therapeutic use; D016035:Pancreas Transplantation; D019397:Pancreas, Artificial; D033581:Stem Cell Transplantation
chemical_list: D006442:Glycated Hemoglobin; D007328:Insulin; D008687:Metformin